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Background. Two community trials conducted from 2012 to 2018 in the Republic of Congo and the Democratic Republic of
the Congo demonstrated the efficacy of semiannual mass drug administration (MDA) with albendazole (ALB) alone on lymphatic
filariasis (LF). However, a high interindividual heterogeneity in the clearance of infection was observed.
Methods. We analyzed trial data to assess the effect of individual adherence to ALB MDA on clearance of circulating filarial antigenemia
(CFA) and microfilaremia. Community residents were offered a single dose of ALB every 6 months and tested for LF with a rapid test for
CFA at baseline and then annually. CFA test results were scored on a semiquantitative scale. At each round, microfilaremia was assessed in
CFA-positive individuals. All CFA-positive individuals for whom at least 1 follow-up measure was available were included in the analyses.
Parametric survival models were used to assess the influence of treatment adherence on LF infection indicators.
Results. Of 2658 individuals enrolled in the trials, 394 and 129 were eligible for analysis of CFA and microfilaremia clearance,
respectively. After adjusting for age, sex, and initial CFA score, the predicted mean time for clearing CFA was shorter in persons
who had taken 2 doses of ALB per year (3.9 years) than in persons who had taken 1 or 0 dose (4.4 and 5.3 years; P < .001 for both).
A similar pattern was observed for microfilaremia clearance.
Conclusions. These results demonstrate a clear dose-response relationship for the effect of ALB on clearance of CFA and
microfilaremia.
Keywords. albendazole; lymphatic filariasis; mass drug administration; treatment adherence; parametric survival analysis.
Lymphatic filariasis (LF) is a mosquito-borne parasitic infection caused mainly by Wuchereria bancrofti. The strategy for LF
elimination is to interrupt the transmission cycle between humans and vectors. In African countries where onchocerciasis is
endemic, programs provide annual mass drug administration
(MDA) with ivermectin (IVM) plus albendazole (ALB). Bednets
are also often provided to limit mosquito exposure. Treatment
with IVM and ALB reduces the density of the larval stages of the
parasite (microfilariae [Mf]) in the blood. However, MDA has to
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be repeated for many years because these drugs have a limited efficacy for killing adult worms [1]. In areas where LF is coendemic
with loiasis, another filarial infection caused by Loa loa, this
strategy is dangerous because IVM can induce serious adverse
events (SAEs) in people with very high L. loa microfilarial
densities (MFD) [2]. In these areas, alternative strategies have
to be implemented. Previous clinical trials that compared the effects of various drugs on W. bancrofti MFD suggested that treatment with ALB alone might reduce MFD, albeit at a slower rate
than after combined treatment with IVM and ALB [3–13]. ALB
does not induce SAEs in patients with high L. loa MFD [14–16].
In 2012, the World Health Organization (WHO) proposed that
MDA with ALB (preferably semiannual, and combined with integrated vector management) might be used to eliminate LF in
areas where loiasis is coendemic [17]. The results of 2 community trials conducted in the Republic of Congo (Congo) and the
Democratic Republic of the Congo (DRC) confirmed that this
strategy was effective. At the first site, where baseline circulating
filarial antigenemia (CFA) and Mf prevalences were moderate

(17.3% and 5.3%, respectively) and treatment adherence was high
(83%–90%), these indicators decreased to 4.7% and 0.3%, respectively, after 3 years of semiannual MDA with ALB alone [18]. In
DRC, where baseline infection prevalences were higher and treatment adherence lower (56%–88%), CFA and Mf prevalences decreased from 31.6% to 8.5% and from 12.0% to 0.9%, respectively,
after 4 years of semiannual MDA with ALB [19]. Although MDA
with ALB alone was highly effective at the community level, considerable heterogeneity was observed in parasite clearance at the
individual level; some individuals cleared their infections rapidly, while others remained infected after 8 rounds of MDA. In
this study, we reanalyzed data collected from these 2 community
trials to assess the effect of individual adherence to ALB treatment on the CFA and W. bancrofti microfilaremia clearance rates.
METHODS
Study Populations

The design of the 2 studies has been described elsewhere [18,
19]. In Congo, the study was conducted from 2012 to 2015
in Seke-Pembe, a village located in Mabombo Health District
(Bouenza division). In DRC, the study site consisted of 2 contiguous villages (Mbunkimi and Misay) located in the Kwilu
province, and the trial took place from 2014 to 2018. Study participants were tested for LF infection at baseline and then annually. Both studies were approved by ethics committees and
administrative authorities in the respective countries. Adult
participants signed an informed consent form. Participants
aged <18 years were enrolled only after verbal assent and if 1
parent signed a consent form.
A total of 2658 individuals were examined for LF infection
at least once during the 2 studies. The present analysis included
all individuals who were CFA-positive at the time of their first
test (which was not necessarily performed during the year when
the trial started at the site) and who had at least 1 subsequent
examination. Therefore, individuals who had progressed from
CFA-negative to CFA-positive during the follow-up period and
those who were CFA-negative at all time points tested were not
included in the analysis.
Assessment of W. bancrofti Infection

Annual parasitological assessments were performed for participants aged ≥5 years. LF infections were detected by CFA
testing using point-of-care tests. In Congo, testing was done
with the BinaxNOW Filariasis immunochromatographic card
test (ICT; Alere, Scarborough, ME) in 2012, 2013, and 2014 and
with the Filariasis Test Strip (FTS; Alere, Scarborough, ME) in
2015. All antigen testing in DRC was performed with FTS. ICT
and FTS results were scored semiquantitatively (0, 1, 2, or 3 according to the relative intensities of the test and control lines)
[18, 20]. All CFA-positive individuals were invited to return
for blood sampling between 10:00 PM and 1:00 AM for assessment of W. bancrofti microfilaremia. MFDs were based on the

arithmetic mean of the counts of two 70-µL-thick blood smears
and expressed as microfilariae per milliliter.
Drug Distribution and Assessment of Treatment Adherence

CFA-negative individuals were treated with a single tablet of
ALB (400 mg) immediately after antigen testing under the direct observation of investigators. Those with positive CFA test
results were treated with ALB just after collection of night blood
for Mf testing. Residents who had not participated in the parasitological survey were also offered ALB treatment.
All treatments were provided under the supervision of a local
healthcare worker who was also responsible for conducting a
population census before each semiannual MDA. Every treatment was recorded in a drug treatment register. In addition,
during the annual assessment visits, we asked the participants
if they had received ALB during the previous MDA campaign,
which was 6 months earlier. Therefore, for each year of the
study, we could determine for each participant whether he/she
had taken 2, 1, or 0 ALB tablets.
Sociodemographics and Risk Factors for LF

At inclusion, we collected information about sex and age. At
each visit using a standardized 1-page questionnaire, we also
collected sociodemographic characteristics and habits that are
known to be risk factors for LF, such as bednet usage and occupation (fishing, hunting, and farming), and regularly sleeping
outside of the village in the bush [21, 22].
Statistical Analyses

The events analyzed are clearance of CFA (the transition from
a positive to a negative CFA test during follow-up) and clearance of microfilaremia. We used survival analysis methods
[23] to account for the individual follow-up nature of the data.
The start date for the survival analysis was the first visit (index
date). Individual observations were censored at the end of the
follow-up or at the date of the event (date of the annual parasitological survey). Each participant’s data were considered for
calculation of cumulative person-years in the survival analysis.
We considered the following covariates for the analysis: sex,
initial MFD (placed into 3 categories of similar sample size: 1
to 150, 150 to 300, and > 300 Mf/mL), initial CFA score (from
1 to 3), a history of fishing as an occupation (yes or no), and a
history of regularly sleeping in the bush (yes or no).
We also considered the following time-varying covariates:
age (categorized according to interquartile and median values:
5–17, 18–30, 31–45, and ≥46 years), number of ALB tablets
taken during the previous year (0, 1, or 2), bednet use during the
previous night (yes or no), and the CFA test used (ICT or FTS).
Univariate analysis of clearance rates was conducted using
Mantel-Haenszel tests. Clearance rates represent the probability
of occurrence of clearance in a specified period of time.
We used a parametric survival model with accelerated failure
time [24] to estimate the influence of time-varying variables on
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infection clearance (time-to-event) [25]. Several time distributions that do not require meeting the proportional risk assumption were tested according to the Akaike information criterion
(AIC). For the survival models, random effects, at both village
and household levels, were assessed using results of likelihoodratio tests. Results are presented as time ratios with 95% confidence intervals. Time ratios represent time differences to event
according to the reference category. Sociodemographic data,
occupation, initial infection intensity (CFA and/or MFD), and
the number of ALB tablets taken each year were included in the
CFA and microfilaremia clearance survival models. The type of
test (ICT or FTS) was included in the CFA clearance model. The
fitted models used to estimate average times to clear CFA and
microfilaremia included all explanatory variables.
A mixed model with random effect at the individual level was
used to describe changes in MFD according to time, treatment
history, and sociodemographic information. Several transformations (linear, quadratic, first-order fractional polynomials, and
second-order fractional polynomials) were tested for the time
variable, and selection was made according to the AIC. As for
CFA clearance analysis, random effects at village and household
levels were assessed. Last, the significance of relevant interaction terms was assessed (age and sex, age and initial CFA score,
age and initial MFD, age and number of ALB treatments taken,
sex and initial CFA score, sex and initial MFD, sex and number
Table 1.

of ALB treatments taken) for CFA and microfilaremia clearance
and MFD change analyses. All analyses were performed using
STATA v.15.1 software (StataCorp, LP, College Station, TX).
RESULTS
Study Participants

Of the 2658 participants enrolled in the studies, 879 were tested
only once; 22 who were CFA-negative at baseline acquired CFA
(15 in DRC and 7 in Congo), and 1363 were CFA-negative at
baseline and all follow-up times. Thus, observations from 394
participants were available for analysis of CFA clearance for a
total of 1369 person-years of follow-up and 203 CFA clearance
events. For the microfilaremia clearance analysis, 129 individuals had a total of 400 person-years of follow-up with 100
microfilaremia-clearance events. The survival data concerning
nontime-varying variables are summarized in Table 1.
CFA and Microfilaremia Clearance Rates

Clearance rates with significance values are presented in
Table 2. The probability of CFA clearance was negatively
correlated with initial CFA score, and the probability of
microfilaremia clearance was negatively correlated with initial MFD. A history of sleeping regularly in the bush decreased the probability of CFA clearance. CFA clearance was

Survival Data for Time Constant Variables Used in Circulating Filarial Antigenemia and Microfilaremia Survival Models
CFA Clearance

Variable
Sex
Age at inclusion, y

CFA score at inclusion

Bednets use at inclusion
Fishing activities at inclusion
History of sleeping outside at inclusion
Village

Study site
Initial microfilarial density

Category

Person-years

Microfilaremia Clearance
Person-years

No. of Events

1369

203

400

100

Male

754

112

232

61

Female

615

91

168

39

5–17

304

47

87

22

18–30

349

48

92

23

31–45

402

59

113

24

≥46

314

49

108

31

1

488

128

30

9

2

352

51

91

28

3

529

24

279

63

No

561

82

138

33

Yes

808

121

262

67

No

596

100

161

43

Yes

699

95

211

52

No

953

159

248

63

Yes

408

44

144

36

Misay (DRC)

297

39

85

21

Mbunkimi (DRC)

660

79

199

49

Seke Pembe (Congo)

412

85

116

30

Bouenza (Congo)

957

118

284

70

Kwilu (DRC)

412

85

116

30

144

44

77

22

179

34

0–150 Mf/mL
151–300 Mf/mL
>300 Mf/mL

Abbreviation: CFA, circulating filarial antigenemia; DRC, the Democratic Republic of the Congo; Mf, microfilariae.
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No. of Events

Table 2.

Univariate Clearance Rates for Circulating Filarial Antigenemia and Microfilaremia
CFA

Variable

Category

14.8

12.9 to 17.0

Sex

Male

14.8

12.0 to 18.2

Female

14.8

12.3 to 17.9

5–17

15.5

11.6 to 20.6

18–30

13.7

10.4 to 18.2

31–45

14.7

≥46

15.6

1

26.2

22.1 to 31.2

2

14.5

11.0 to 19.1

Age at inclusion, y

CFA score at inclusion

Fishing activity at inclusion
History of sleeping outside at inclusion
Village

Study site
Initial microfilarial density

95% CI

PValue

Clearance Ratea

95% CI

25.0

20.5 to 30.4

26.3

20.4 to 33.8

23.2

17.0 to 31.8

25.3

16.6 to 38.4

25.0

16.6 to 37.6

11.4 to 18.9

21.2

14.2 to 31.7

11.8 to 20.6

28.7

20.2 to 40.8

30.0

15.6 to 57.6

30.8

21.2 to 44.6

22.6

17.6 to 28.9

23.9

17.0 to 33.6

25.6

20.1 to 32.5

19.0

14.1 to 25.6

16.2

12.4 to 21.3

26.7

19.8 to 36.0

24.6

18.8 to 32.2

24.7

16.1 to 37.9

24.6

18.6 to 32.6

25.9

18.1 to 37.0

24.6

19.5 to 31.1

25.9

18.1 to 37.0

1–150 Mf/mL

30.6

22.7 to 41.0

151–300 Mf/mL

28.6

18.8 to 43.4

>300 Mf/mL

19.0

13.6 to 26.6

3
Bednets use at inclusion

Clearance Ratea

Microfilaremia
b

4.5

.989
.859

<.0001

3.0 to 6.8

No

14.6

11.8 to 18.1

Yes

14.9

12.5 to 17.9

No

16.8

13.8 to 20.4

Yes

13.6

11.1 to 16.6

No

16.7

14.3 to 19.5

Yes

10.8

8.0 to 14.5

Misay (DRC)

13.1

9.6 to 18.0

Mbunkimi (DRC)

12.0

9.6 to 14.9

Seke Pembe (Congo)

20.6

16.7 to 25.5

Bouenza (Congo)

12.3

10.3 to 14.8

Kwilu (DRC)

20.6

16.7 to 25.5

.677
.671
.042
<.0001

<.001

PValueb
.543
.739

.184

.752
.444
.696
.859

.826
.036

Abbreviations: CFA, circulating filarial antigenemia; CI, confidence interval; DRC, the Democratic Republic of the Congo; Mf, microfilariae.
a

Calculated for 100 person-years.
P value is calculated from significance tests using the Mantel-Haenszel method based on stratified rate ratios.

b

also more likely in Congo than in DRC. The probabilities
for clearance of CFA for each of the 39 treatment patterns
during the 5-year period are included in the Supplementary
Materials 1.
Parametric Survival Multivariate Models for the Clearance of CFA and
Microfilaremia

Results from the parametric survival model analyses are presented in Table 3. Log-logistic distribution and log-normal
distribution were the best fits for time in the CFA and
microfilaremia clearance models, respectively. No interactions
between covariates were found. A random effect at the village
level (P = .0277) was included in the CFA clearance model
(intraclass correlation coefficient = 7.27%), but this was not
significant in the microfilaremia clearance model (P = .346).
CFA score at inclusion, frequently sleeping outdoors, and type
of CFA test were all significantly associated with CFA clearance.
Times to CFA clearance were significantly longer in individuals with higher initial CFA scores. Sleeping outdoors significantly increased the time to CFA clearance. Assessment of the
CFA by ICT decreased the observed duration to CFA clearance.
Predicted average time for clearing CFA was shorter in those
who had taken 2 doses of ALB per year (3.9 years) than in those
who had taken 1 or 0 dose (4.4 and 5.3 years, P < .001 for both

comparisons). Microfilaremia clearance had a similar pattern:
individuals who had taken 2 doses of ALB per year became
amicrofilaremic after a mean time of 3.1 years, whereas those
who had taken 1 or 0 dose per year needed 3.6 (P < .001) and
5.9 years (P < .001), respectively, to clear their microfilaremia.
Time to microfilaremia clearance was also significantly longer
in individuals with higher initial MFD.
Changes in MFD Over Time

No transformation of time was required for the model. Neither
the village- (P = .496) nor the household-level (P = .529)
random effect was significant in the mixed model. Results
from the mixed model with no random effect are presented
in Table 4. MFD reduction was more rapid when individuals
were adherent with MDA. The decrease in MFD was not significantly different in those who had taken 0 or 1 dose of ALB per
year. Figure 1 shows predicted changes in MFD according to the
number of doses taken per year with time transformation into a
fractional polynomial of order 2 (see Supplementary Materials
2). All predictions were adjusted for sex, age, and initial MFD.
Differences in slopes were highly significant between 0 and 2
doses of ALB (P = .009) and between 2 and 1 dose (P = .004)
but not significant between 1 and 0 dose (P = .419).
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Table 3.

Results From Parametric Survival Models for Circulating Filarial Antigenemia With Village as a Random Effect and Microfilaremia Clearance
CFA Clearance

Variable

Category

Adjusted Time Ratio

Sex

Female

Ref.

Male

1.01

5–17

Ref.

18–30

1.00

.93 to 1.07

.910

31–45

1.02

.95 to 1.08

.515

≥46

1.00

.93 to 1.07

.992

1

Ref.

2

1.14

1.08 to 1.20

<.001

3

1.40

1.31 to 1.51

<.001

0 dose

1.35

1.26 to 1.45

1 dose

1.12

1.06 to 1.19

2 doses

Ref.

No

Ref.

Yes

0.98

No

Ref.

Yes

0.97

No

Ref.

Yes

1.09

Filariasis Test Strip

Ref.

Immunochromatographic card test

0.76

Age, y

Initial CFA score

Annual treatment

Bednets
Fishing
Sleeping outside
Test used
Initial microfilarial density

95% CI

Microfilaremia Clearance
PValue

Adjusted Time Ratio

95% CI

PValue

Ref.
.96 to 1.06

.718

0.94

.84 to 1.05

.281

1.02

.87 to 1.20

.769

1.15

.98 to 1.34

.082

1.03

.89 to 1.20

.644

0.91

.74 to 1.11

.357

1.00

.83 to 1.21

<.001

1.82

1.46 to 2.27

<.001

<.001

1.18

1.04 to 1.34

.008

.84 to 1.04

.243

.95 to 1.18

.305

.94 to 1.18

.397

Ref.

Ref.
.982

Ref.
Ref.
.94 to 1.03

.515

0.94
Ref.

.92 to 1.02

.280

1.06
Ref.

1.03 to 1.16
.69 to .85

.002

1.05

<.001

1–150 Mf/mL

Ref.

151–300 Mf/mL

1.04

.92 to 1.19

>300 Mf/mL

1.28

1.14 to 1.43

.514
<.001

Abbreviations: CFA, circulating filarial antigenemia; CI, confidence interval; Mf, microfilariae.

Table 4.

Mixed Model Results for the Evolution of Microfilariae Density

Variable

Category

Adjusted Coefficients

Sex

Female

Ref.

Male

−26.6

5–17

Ref.

18–30
31–45

95% Confidence Interval

P Value

−131.2 to 77.9

.618

−93.1

−236.6 to 50.4

.203

35.3

−103.6 to 174.1

.619

≥46

−59.6

−196.8 to 77.5

.394

1

Ref.

2

−37.8

−250.9 to 175.4

.728

3

52.6

−156.8 to 262.0

.622

Initial microfilarial density

1–200 Mf/mL

Ref.

> 200 Mf/mL

221.3

Bednets

No

Ref.

Yes

29.9

No

Ref.

Yes

–18.5

No

Ref.

Yes

−21.0

0 dose

Ref.

1 dose
2 doses
Time
Annual treatment interacted with time

Age, y

Initial circulating filarial antigenemia score

Fishing
Sleeping outside
Annual treatment

Abbreviation: Mf, microfilariae.
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124.3 to 318.3

<.001

−61.9 to 121.8

.523

−133.9 to 96.9

.753

−138.5 to 96.5

.753

177.8

−472.3 to 828.0

.592

416.6

–217.3 to 1050.5

.198

Continuous

−22.0

−174.6 to 130.5

.777

0 dose

Ref.

1 dose

−68.6

−234.9 to 97.7

.419

2 doses

–210.9

–369.3 to –52.44

.009

Figure 1. Predictions of Mf density evolution according to time (fractional polynomial of order 2) and adherence with mass drug administration (A, 0 dose per year; B, 1
dose per year; C, 2 doses per year). Full model and time transformations are available in Supplementary Materials 2. Abbreviation: Mf, microfilariae.

DISCUSSION

The WHO’s provisional recommendation to use semiannual
MDA with ALB alone to control LF in areas where L. loa is
coendemic was based on thin evidence. The few trials [5, 11–13]
that had evaluated the effect of a single dose of ALB on LF infection had demonstrated a modest effect of the drug on MFD. In
addition, 2 meta-analyses of the efficacy of a single dose of ALB
alone on Mf and CFA prevalences concluded that this treatment
would induce only a small to nonexistent decrease in these outcomes at 3, 6, or 12 months post-treatment [26, 27].
We conducted community trials in 2 settings to evaluate the
impact of semiannual MDA with ALB on LF [18, 19]. However,
a major methodological limitation of these trials was that the
effect of semiannual treatment was not directly compared with
that of annual treatment or no treatment. Thus, the analyses
presented here provide important information regarding the
added value of semiannual ALB treatment vs annual MDA or
no treatment on LF infection parameters. Our longitudinal analyses from infected persons clearly demonstrate a dose-response
effect for ALB treatment on CFA and on microfilaremia. Our
results show that good adherence leads to faster clearance of

LF infection in individuals. Both clearances were significantly
associated with the number of doses of ALB taken annually and
with initial infection levels. A lower initial CFA score was associated with a higher probability of CFA clearance. Therefore,
the knowledge of the individual semiquantitative results at
baseline may be useful to improve planning for LF elimination
programs. The use of the ICT was associated with an increased
probability of CFA clearance relative to use of the FTS, and this
is likely due to the higher sensitivity of the FTS [28]. Although
baseline CFA scores were not associated with more rapid clearance of microfilaremia, higher initial MFD increased the time
required for total microfilaremia clearance.
Regarding an individual’s exposure and habits, individuals who slept regularly outdoors took longer to clear CFA.
This was probably due to reinfection; prior studies have identified sleeping outdoors as a significant risk factor for LF in
central Africa [21, 22]. However, the use of bednets or a history of fishing were not significantly associated with the clearances. Although the nonuse of bednets has been shown to be
a risk factor for LF infection, their use in infected individuals
(without MDA) was not effective for clearing infections or for
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reducing Mf prevalence in the time frames (3 or 4 years) of this
study [29]. Data on the relationship between bednet usage and
treatment adherence are included in Supplementary Materials
3. Hunting and agricultural activities were not included in the
models because the numbers of hunters and farmers were small
at the study sites and inclusion of these occupations would have
destabilized the models. Individuals were more likely to clear
CFA after MDA in Congo than in DRC. This might be due to
the fact that therapeutic coverage was higher and more constant
and baseline infection prevalence lower in Congo than in DRC,
which may reduce transmission and, therefore, the probability
that reinfection occurs.
The activity of ALB alone for LF has important implications for current protocols that rely heavily on CFA surveys in
school-aged children for MDA-stopping decisions and postMDA surveillance. Indeed, since soil-transmitted helminth
programs routinely only treat children, using this demographic
as a sentinel for MDA-stopping decisions may underestimate
the level of community-wide transmission because LF will tend
to be less prevalent in children who are treated more frequently
than adults.
We elected to use parametric survival models to analyze
these data because these models are more flexible and allow
longitudinal analyses with time-varying variables (ie, ALB intake). In addition, they are more informative than nonparametric approaches because they provide time ratios, enable
predictions of mean and median survival times, and have more
power than semiparametric models. Log-logistic distribution
for the CFA clearance model and log-normal distribution for
the microfilaremia clearance model were the best fits for our
data, and they have the advantage of not requiring proportional
risk assumptions, unlike conventional Cox survival models.
The presence of bias cannot be excluded. Prevalence bias may
be present. However, fewer than 11% of the population (8.5%
and 10.4% for the CFA and microfilaremia clearance models,
respectively) had taken ALB prior to our study. We believe that
this bias, if it exists, would have had very little impact on our results. In addition, participation bias cannot be excluded: people
with a high participation frequency in our study may have different characteristics than nonparticipants, including adherence with treatment.
We have mentioned that participation rates in MDA decreased over time, probably reflecting a type of fatigue on the
part of some community members [19]. We believe that we
have demonstrated through these new analyses that participation rates in MDA programs must be maintained at high levels
to accelerate the elimination of LF in individuals and communities. Evidence from this study could be used in social mobilization programs to illustrate the importance of achieving
and sustaining high rates of MDA adherence in LF elimination
programs.
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